Novel report of expression and function of CD97 in malignant gliomas: correlation with Wilms tumor 1 expression and glioma cell invasiveness

Laboratory investigation

Restricted access

Object

The Wilms tumor 1 (WT1) protein—a developmentally regulated transcription factor—is aberrantly expressed in gliomas and promotes their malignant phenotype. However, little is known about the molecular allies that help it mediate its oncogenic functions in glioma cells.

Methods

The authors used short interfering RNA (siRNA) to suppress WT1 expression in glioblastoma (GBM) cells and evaluated the effect of this on GBM cell invasiveness. Gene expression analysis was then used to identify the candidate genes that were altered as a result of WT1 silencing. One candidate target, CD97, was then selected for further investigation into its role by suppressing its expression using siRNA silencing, followed by proliferation and invasion assays.

Results

WT1 levels were reliably and reproducibly suppressed by siRNA application. This resulted in a significant decrease in cellular invasiveness. Microarray analyses identified the gene products that were consistently downregulated (27) and upregulated (11) with WT1 silencing. Of these, CD97 expression was consistently suppressed across the 3 different GBM cell lines studied and was found on further investigation to significantly impact GBM cell invasiveness.

Conclusions

Although CD97 expression in gliomas has not been described previously, we conclude that the possible upregulation of CD97 mediated by WT1 promotes cellular invasiveness—one of the most characteristic and challenging aspects of glial tumor cells. Further studies are needed to clarify the nature of this regulation and its impact, as CD97 could represent a novel target for antiglioma therapies.

Abbreviations used in this paper:ATP = adenosine triphosphate; EGF = epidermal growth factor; GBM = glioblastoma; PDGF = platelet-derived growth factor; qRT-PCR = quantitative reverse transcriptase polymerase chain reaction; SDS = sodium dodecyl sulfate; siRNA = short interfering RNA; VCU = Virginia Commonwealth University; WT1 = Wilms tumor 1.
Article Information

Contributor Notes

Current affiliation for Dr. Van Meter: Pediatric Hematology-Oncology, Department of Pediatrics, VCU School of Medicine.Address correspondence to: William C. Broaddus, M.D., Ph.D., Department of Neurosurgery, Virginia Commonwealth University, P.O. Box 980631, Richmond, Virginia 23298-0631. email: wbroaddus@mcvh-vcu.edu.Please include this information when citing this paper: published online February 7, 2012; DOI: 10.3171/2011.11.JNS111455.

© AANS, except where prohibited by US copyright law.

Headings
References
  • 1

    Aust GEichler WLaue SLehmann IHeldin NELotz O: CD97: a dedifferentiation marker in human thyroid carcinomas. Cancer Res 57:179818061997

    • Search Google Scholar
    • Export Citation
  • 2

    Cheever MAAllison JPFerris ASFinn OJHastings BMHecht TT: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:532353372009

    • Search Google Scholar
    • Export Citation
  • 3

    Chen MYClark AJChan DCWare JLHolt SEChidambaram A: Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression. J Neurooncol 103:871022011

    • Search Google Scholar
    • Export Citation
  • 4

    Clark AJChan DCChen MYFillmore HLDos Santos WGVan Meter TE: Down-regulation of Wilms' tumor 1 expression in glioblastoma cells increases radiosensitivity independently of p53. J Neurooncol 83:1631722007

    • Search Google Scholar
    • Export Citation
  • 5

    Clark AJDos Santos WGMcCready JChen MYVan Meter TEWare JL: Wilms tumor 1 expression in malignant gliomas and correlation of +KTS isoforms with p53 status. J Neurosurg 107:5865922007

    • Search Google Scholar
    • Export Citation
  • 6

    Clark AJWare JLChen MYGraf MRVan Meter TEDos Santos WG: Effect of WT1 gene silencing on the tumorigenicity of human glioblastoma multiforme cells. Laboratory investigation. J Neurosurg 112:18252010

    • Search Google Scholar
    • Export Citation
  • 7

    Dudnakova TSpraggon LSlight JHastie N: Actin: a novel interaction partner of WT1 influencing its cell dynamic properties. Oncogene 29:108510922010

    • Search Google Scholar
    • Export Citation
  • 8

    Dumur CINasim SBest AMArcher KJLadd ACMas VR: Evaluation of quality-control criteria for microarray gene expression analysis. Clin Chem 50:199420022004

    • Search Google Scholar
    • Export Citation
  • 9

    Dumur CISana SLadd ACFerreira-Gonzalez AWilkinson DSPowers CN: Assessing the impact of tissue devitalization time on genome-wide gene expression analysis in ovarian tumor samples. Diagn Mol Pathol 17:2002062008

    • Search Google Scholar
    • Export Citation
  • 10

    Garrido-Ruiz MCRodriguez-Pinilla SMPérez-Gómez BRodriguez-Peralto JL: WT 1 expression in nevi and melanomas: a marker of melanocytic invasion into the dermis. J Cutan Pathol 37:5425482010

    • Search Google Scholar
    • Export Citation
  • 11

    Gerald WLHaber DA: The EWS-WT1 gene fusion in desmoplastic small round cell tumor. Semin Cancer Biol 15:1972052005

  • 12

    Giannini CSarkaria JNSaito AUhm JHGalanis ECarlson BL: Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 7:1641762005

    • Search Google Scholar
    • Export Citation
  • 13

    Gray JXHaino MRoth MJMaguire JEJensen PNYarme A: CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J Immunol 157:543854471996

    • Search Google Scholar
    • Export Citation
  • 14

    Han SLXu CWu XLLi JLLiu ZZeng QQ: The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma. Int J Colorectal Dis 25:6957022010

    • Search Google Scholar
    • Export Citation
  • 15

    Hohenstein PHastie ND: The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 15 Spec No 2:R196R2012006

  • 16

    Huff V: Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer 11:1111212011

  • 17

    Izumoto STsuboi AOka YSuzuki THashiba TKagawa N: Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108:9639712008

    • Search Google Scholar
    • Export Citation
  • 18

    Jomgeow TOji YTsuji NIkeda YIto KTsuda A: Wilms' tumor gene WT1 17AA(−)/KTS(−) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Sci 97:2592702006

    • Search Google Scholar
    • Export Citation
  • 19

    Kreidberg JASariola HLoring JMMaeda MPelletier JHousman D: WT-1 is required for early kidney development. Cell 74:6796911993

    • Search Google Scholar
    • Export Citation
  • 20

    Kwakkenbos MJKop ENStacey MMatmati MGordon SLin HH: The EGF-TM7 family: a postgenomic view. Immunogenetics 55:6556662004

    • Search Google Scholar
    • Export Citation
  • 21

    Liu YChen LPeng SChen ZGimm OFinke R: The expression of CD97EGF and its ligand CD55 on marginal epithelium is related to higher stage and depth of tumor invasion of gastric carcinomas. Oncol Rep 14:141314202005

    • Search Google Scholar
    • Export Citation
  • 22

    Loeb DMEvron EPatel CBSharma PMNiranjan BBuluwela L: Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 61:9219252001

    • Search Google Scholar
    • Export Citation
  • 23

    Mayo MWWang CYDrouin SSMadrid LVMarshall AFReed JC: WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J 18:399040031999

    • Search Google Scholar
    • Export Citation
  • 24

    Miyagi TAhuja HKubota TKubonishi IKoeffler HPMiyoshi I: Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells. Leukemia 7:9709771993

    • Search Google Scholar
    • Export Citation
  • 25

    Oji YInohara HNakazawa MNakano YAkahani SNakatsuka S: Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma. Cancer Sci 94:5235292003

    • Search Google Scholar
    • Export Citation
  • 26

    Oji YMiyoshi SMaeda HHayashi STamaki HNakatsuka S: Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 100:2973032002

    • Search Google Scholar
    • Export Citation
  • 27

    Oji YMiyoshi YKoga SNakano YAndo ANakatsuka S: Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer. Cancer Sci 94:6066112003

    • Search Google Scholar
    • Export Citation
  • 28

    Oji YNakamori SFujikawa MNakatsuka SYokota ATatsumi N: Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci 95:5835872004

    • Search Google Scholar
    • Export Citation
  • 29

    Oji YOgawa HTamaki HOka YTsuboi AKim EH: Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 90:1942041999

    • Search Google Scholar
    • Export Citation
  • 30

    Oji YYamamoto HNomura MNakano YIkeba ANakatsuka S: Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci 94:7127172003

    • Search Google Scholar
    • Export Citation
  • 31

    Oji YYano MNakano YAbeno SNakatsuka SIkeba A: Overexpression of the Wilms' tumor gene WT1 in esophageal cancer. Anticancer Res 24:310331082004

    • Search Google Scholar
    • Export Citation
  • 32

    Oka YSugiyama H: WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects. Immunotherapy 2:5915942010

    • Search Google Scholar
    • Export Citation
  • 33

    Oka YTsuboi AFujiki FLi ZNakajima HHosen N: WT1 peptide vaccine as a paradigm for “cancer antigen-derived peptide”-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide. Anticancer Agents Med Chem 9:7877972009

    • Search Google Scholar
    • Export Citation
  • 34

    Perugorria MJCastillo JLatasa MUGoñi SSegura VSangro B: Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy. Cancer Res 69:135813672009

    • Search Google Scholar
    • Export Citation
  • 35

    Scharnhorst Vvan der Eb AJJochemsen AG: WT1 proteins: functions in growth and differentiation. Gene 273:1411612001

  • 36

    Scholz HWagner KDWagner N: Role of the Wilms' tumour transcription factor, Wt1, in blood vessel formation. Pflugers Arch 458:3153232009

    • Search Google Scholar
    • Export Citation
  • 37

    Sugiyama H: WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol 40:3773872010

  • 38

    Tamaki HOgawa HOhyashiki KOhyashiki JHIwama HInoue K: The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 13:3933991999

    • Search Google Scholar
    • Export Citation
  • 39

    Ueda TOji YNaka NNakano YTakahashi EKoga S: Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas. Cancer Sci 94:2712762003

    • Search Google Scholar
    • Export Citation
  • 40

    Van Meter TEDumur CIHafez NGarrett CFillmore HLBroaddus WC: Microarray analysis of MRI-defined tissue samples in glioblastoma reveals differences in regional expression of therapeutic targets. Diagn Mol Pathol 15:1952052006

    • Search Google Scholar
    • Export Citation
  • 41

    Veninga HBecker SHoek RMWobus MWandel Evan der Kaa J: Analysis of CD97 expression and manipulation: antibody treatment but not gene targeting curtails granulocyte migration. J Immunol 181:657465832008

    • Search Google Scholar
    • Export Citation
  • 42

    Wagner NMichiels JFSchedl AWagner KD: The Wilms' tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo. Oncogene 27:366236722008

    • Search Google Scholar
    • Export Citation
  • 43

    Wang TWard YTian LLake RGuedez LStetler-Stevenson WG: CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood 105:283628442005

    • Search Google Scholar
    • Export Citation
  • 44

    Wang ZAhmad ALi YKong DAzmi ASBanerjee S: Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta 1806:1221302010

    • Search Google Scholar
    • Export Citation
  • 45

    Wang ZYQiu QQEnger KTDeuel TF: A second transcriptionally active DNA-binding site for the Wilms tumor gene product, WT1. Proc Natl Acad Sci U S A 90:889689001993

    • Search Google Scholar
    • Export Citation
  • 46

    Yang LHan YSuarez Saiz FMinden MD: A tumor suppressor and oncogene: the WT1 story. Leukemia 21:8688762007

  • 47

    Yona SLin HHSiu WOGordon SStacey M: Adhesion-GPCRs: emerging roles for novel receptors. Trends Biochem Sci 33:4915002008

  • 48

    Zhang LWang LRavindranathan AMiles MF: A new algorithm for analysis of oligonucleotide arrays: application to expression profiling in mouse brain regions. J Mol Biol 317:2252352002

    • Search Google Scholar
    • Export Citation
  • 49

    Zhao YXiao AdiPierro CGCarpenter JEAbdel-Fattah RRedpath GT: An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9. Am J Pathol 176:303230492010

    • Search Google Scholar
    • Export Citation
TrendMD
Cited By
Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 200 200 10
Full Text Views 157 96 2
PDF Downloads 98 50 2
EPUB Downloads 0 0 0
PubMed
Google Scholar